Skip to main content
Navigate Up
Sign In
 

FDA Advisors All In on Vascepa for CV Risk Reduction


Another issue with Amarin's proposed broader indication was the component of cardiovascular death risk reduction when there were not enough trial data to support this, cautioned Cecilia Low Wang, of the CU School of Medicine.
 

Medpage Today, Dec. 14, 2019

Read more